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The clinical relevance of the somatostatin receptor subtype 2 (sst2) is well defined in neuroendocrine tumors but it is still a matter of
debate whether its expression may have a role also in other tumors not arising from the neuroectoderm. We investigated the prognostic value
of the expression levels of sst2 mRNA in a consistent group of patients affected by colorectal cancer. Survival analysis of cancer-related death
showed that patients with a high sst2 mRNA expression had an unfavourable outcome ( p =0.037) and a significantly shorter disease-free
survival ( p =0.008). Surprisingly, our findings suggest that sst2 gene overexpression is a feature of colorectal tumors that have a negative
outlook; in addition, it may allow additional insight into conventional therapeutic approaches for more aggressive tumors, whose prognosis
needs to be improved.
D 2005 Elsevier B.V. All rights reserved.Keywords: sst2 mRNA; Real time RT-PCR; Survival1. Introduction
Somatostatin (SS) is a widely distributed, multifunctional
inhibitory peptide hormone which is involved in multiple
cellular activities. In particular, SS regulates cell secretion
and proliferation through a family of specific G-protein
coupled receptors (ssts) [1]. The role of one of these
receptors in particular, namely, type 2 (sst2), which strongly
mediates the antiproliferative action of SS and shows high
affinity for the currently available SS analogs, has been
clearly established for both endocrine and neuroendocrine
tumors [2]. Indeed the presence of sst2 provides a strong0167-0115/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
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endocrine and neuroendocrine tumors expressing the recep-
tor [3]. Also, we reported that the expression of sst2 was
positively related to patient outcome in the childhood tumor
neuroblastoma, therefore giving relevant insights in terms of
patients overall and disease-free survival [4].
Many recent studies showing that common solid tumors,
such as colorectal and breast cancer, often express these
receptors, have led to growing interest in the clinical utility
of ssts as prognostic and therapeutic targets for these tumors
also. With respect to colon cancer, therapy with SS analogs
has been generally disappointing in terms of both survival
and disease stabilization in the majority of the reported trials
performed randomly on patients affected by this tumor [5–
7]. In only one study a significant advantage in terms of
survival has been reported [8]. We believed that these
findings could be explained by several factors, such as the32 (2005) 23 – 26
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trials, the inappropriate selection of patients (highly
disseminated disease), and the lack of investigation regard-
ing the presence of ssts in the tumors [9]. Indeed, in the
aforementioned trials the ssts status of patients has not been
elucidated before initiation of therapy, further complicating
the interpretation of the findings obtained so far [10].
Regarding this aspect, the few studies that were performed
to characterize the pattern of expression of different ssts
subtypes in colon cancer have provided controversial results
[11–14], which in our opinion could also be explained by
the methods employed. Furthermore, our data on neuro-
blastoma clearly showed that only a quantitative determi-
nation of sst2 gene expression had a significant prognostic
value [4].
In our previous study we evaluated sst2 mRNA
expression by quantitative RT-PCR in sporadic colorectal
carcinomas and in their paired adjacent unaffected tissues
[15]. Since long-term follow-up has now reached a
significant period, we investigated whether the quantitative
determination of sst2 may have had a prognostic relevance
in the same group of patients.2. Materials and methods
2.1. Patients and samples
Tissues were obtained from 96 patients with sporadic
colorectal carcinoma, scheduled for elective resection.
Informed consent was previously obtained from all
patients. For all patients at least one sample of both
neoplastic and normal tissue (taken 10 cm apart from the
neoplasm) were obtained. Samples were immediately snap
frozen and stored in liquid nitrogen. Tumor was localized
in the right colon in 33 patients, in the left colon (12 in the
descending, and 21 in the sigmoid colon) in 32 patients,
and in the rectal portion in the remaining 31 patients.
Histological examination was performed routinely in all
cases. An adequate number of sections were sampled from
each tumor. Tumor histotype and grade of differentiation
were defined according to the World Health Organization
criteria [16]. The pattern of cancer growth was assessed as
expanding (when the tumor border was clearly demar-
cated) and as infiltrating (when cancer cells spread into the
surrounding tissues without a distinct border) [17]. All
cases were staged according to the original Dukes’ system.
According to the histopathological grading, 5 tumors were
G1, 61 were G2, 8 were G3 and 16 were colloid. Six were
in situ tumors.
Total RNAwas extracted from each sample with RNeasy
Kit (Quiagen S.p.A., Milan, Italy). Since sst2 is an intron-
less gene, each RNA sample was first submitted to a
conventional PCR with the same primers and cycling for
sst2, but without reverse transcription, to exclude the
presence of residual genomic DNA in the extracted speci-mens. Samples with residual DNA were treated with
DNAse, till the disappearance of any DNA trace.
2.2. Quantitative evaluation of sst2 mRNA expression
The primers and probe for sst2 mRNA quantification to
use with the ABI Prism 7700 Sequence Detection System
were described elsewhere [18]. Four hundred nanograms of
total RNA were reverse-transcribed according to recom-
mended protocol. The PCR mixture contained primers (200
mM each) and 200 nM of the Taqman probe, in a final
volume of 25 microl. Amplification and detection were
performed with the ABI Prism 7700 Sequence Detection
System with the following profile: one step at 50 -C for 2
min, one step at 95 -C for 10 min, and 40 cycles at 95 -C for
30 s and 60 -C for 1 min. The amount of product was
measured by interpolation from a standard curve with RNA
extracted from neuroblastoma cell line CHP404, which
over-expresses sst2 mRNA. One microgram of CHP404
RNA was reverse transcribed and cDNA is then serially
diluted to obtain 5 standard solutions to be used in the PCR
reaction to generate the reference curve [18].
2.3. Statistical analysis
Statistical analysis was carried out using the SPSS
software package (SPSS INC, Chicago, IL). For analysis
of follow-up data, life table curves were calculated using
Kaplan–Meier method and survival distribution were
compared by log-rank statistics. The primary end point
was cancer-related survival, as measured from the date of
surgery to the time of last follow-up or cancer-related death.
The joint effects with already recognized prognostically
relevant variables were examined via Cox proportional
hazard analysis. Pattern of growth and Duke’s stage were
entered stepwise forward into the model to test these
covariables for possible joint effects with high/low levels
of sst2 expression. Differences were considered statistically
significant with p <0.05.3. Results
Our results showed that sst2 was variably expressed in all
colon cancers investigated and, on average, tumor samples
expressed a lower amount of sst2 mRNA than the
unaffected samples [15]. Taking into account the variability
due to the assay procedure, we assumed that sst2 mRNA
was over-expressed in the tumor tissue when its concen-
tration was at least twice the value in the respective adjacent
unaffected tissue. Survival analysis of cancer-related death,
obtained by comparing tumors over-expressing sst2 mRNA
(cancer >2-fold adjacent unaffected tissue) vs tumors with a
low sst2 mRNA expression (cancer 2-fold adjacent
unaffected tissue), showed a significant correlation of high
expression of sst2 mRNA with unfavourable outcome (log-
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Fig. 1. Cumulative cancer-related survival in patients over-expressing sst2
mRNA [cancer mRNA expression >2-fold than in adjacent unaffected
tissue (T >2 N)] vs tumors with a low sst2 mRNA expression [cancer
mRNA expression 2-fold than in adjacent unaffected tissue (T2 N)],
showed a significant correlation between high expression of sst2 mRNA
and unfavorable outcome (upper panel, log-rank test, p =0.0375) and
disease-free survival (lower panel, p =0.008). Analysis of distributions were
calculated using Kaplan–Meier method and compared by log-rank test.
Table 1
Univariate and multivariate cox regression analysis for 96 patients with
resected colon carcinoma
Variable Univariate Multivariate analysis
C.C. Raggi et al. / Regulatory Peptides 132 (2005) 23–26 25rank test, p =0.037) and shorter disease-free survival
( p =0.008) (see Fig. 1). With respect to some well-
established prognostic factors (stage according to Duke
classification, and growth pattern), cancer sst2 overexpres-
sion correlated significantly with overall survival in
univariate Cox regression analysis. In multivariate analysis,
sst2 mRNA over-expression was shown to be an independ-
ent prognostic parameter for overall survival ( p =0.027)
(see Table 1).
analysis
p p Relative
Risk
Exp (B)
Exp (B)
95% Cl
Pattern of growth 0.048 0.114 0.179 0.021–1.511
Infiltrating vs pushing
Dukes’ Stage 0.022 0.283 2.123 0.537–8.395
A+B vs D+C
sst2 mRNA ratioa 0.037 0.027 5.875 1.225–28.174
>2 vs 2
a sst2 mRNA was over-expressed in colon cancer when its concentration
was at least twice than in the respective adjacent not affected tissue.4. Discussion
As already mentioned, according to the data obtained so
far there is clear evidence that SS analogs are highly
effective in the symptomatic management of patients with
neuroendocrine tumors [19,20]. This still has to be
elucidated for malignancies not arising from the neuro-
ectoderm, in which the presence of ssts has though been
demonstrated.Also, we showed that in neuroblastoma the quantitative
determination of sst2 gene expression could provide
relevant prognostic information, independently from the
other well known prognostic markers [4].
In our previous study [15], beside a variable presence of
sst2 in all colon tumors investigated, we did not observe any
statistically significant relationship between sst2 expression
and any of the parameters examined such as localization,
grading and stage of the disease. However loss of sst2
seemed to be a relevant event in patients with high
preoperative concentration of carcinoembryonic antigen, a
poor prognostic indicator for colorectal carcinoma [15].
Our current findings on the same group of patients do not
confirm this previous observation; surprisingly, they show a
significant correlation between high expression of sst2
mRNA, unfavourable outcome and shorter disease-free
survival.
Indeed, these findings are in contrast not only with the
aforementioned data in neuroblastoma, but also with results
we recently obtained in a prospective study on a large group
of patients affected by breast cancer [21]. In the latter we
found an upregulation of sst2 mRNA expression in those
breast tumors that on the basis of conventional predictive
parameters are expected to have a better prognosis.
In our opinion, the clinical and pathological relevance of
the presence of ssts in human primary non-neuroendocrine
tumors, such as colorectal cancer, remains unclear. More-
over, the clinical studies with SS analogs performed up to
now in patients affected by colon cancer do not justify the
routine use of such treatment in the management of this
malignancy. Indeed clinical evidence of the antiproliferative
effect of SS analogs is restricted to acromegalics and to
some patients with gastrointestinal neuroendocrine tumors,
i.e. to tumors with a very high sst2 density [22].
Beside their prognostic relevance, our results may
suggest the opportunity of adding SS analogs to conven-
tional treatment modalities in a specific subset of patients
affected by colon cancer. Tumors with a relatively higher
sst2 expression may represent the ideal target for a treatment
based on SS analogs, particularly in conjunction with radio-
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mediated therapy [23]. This is particularly important for
tumors which turn out to be more aggressive, and for whom
conventional therapies need to be improved.
Finally, it remains to be elucidated if the variable
expression of sst2 in colorectal cancer might have a
relevance in exploiting the therapeutic effects of SS analogs,
and therefore if investigation of ssts tumor status before
initiation of therapy could represent a tool for predicting the
efficacy of cold or radio-labelled SS analogs.References
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